Iuliana Vaxman, MD, Mayo Clinic, Rochester, MN, discusses the results of a study evaluating the safety and efficacy of daratumumab, carfilzomib, pomalidomide, and elotuzumab in patients with POEMS syndrome treated at Mayo Clinic. The study found that patients treated with these agents achieved deep responses, and there were no treatment-related deaths. In the future, it is important to assess these drugs in randomized clinical trials and determine optimal treatment sequencing strategies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

свернуть